228 related articles for article (PubMed ID: 31446998)
1. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
[TBL] [Abstract][Full Text] [Related]
3. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
4. Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.
Heavey S; Godwin P; Baird AM; Barr MP; Umezawa K; Cuffe S; Finn SP; O'Byrne KJ; Gately K
Cancer Biol Ther; 2014 Oct; 15(10):1367-77. PubMed ID: 25025901
[TBL] [Abstract][Full Text] [Related]
5. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
6. Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin.
Yang Z; Fang S; Di Y; Ying W; Tan Y; Gu W
PLoS One; 2015; 10(3):e0121547. PubMed ID: 25799148
[TBL] [Abstract][Full Text] [Related]
7. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
[TBL] [Abstract][Full Text] [Related]
8. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.
Barr MP; Gray SG; Hoffmann AC; Hilger RA; Thomale J; O'Flaherty JD; Fennell DA; Richard D; O'Leary JJ; O'Byrne KJ
PLoS One; 2013; 8(1):e54193. PubMed ID: 23349823
[TBL] [Abstract][Full Text] [Related]
10. Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells.
Milone MR; Lombardi R; Roca MS; Bruzzese F; Addi L; Pucci B; Budillon A
J Cell Physiol; 2019 Jun; 234(6):9077-9092. PubMed ID: 30362533
[TBL] [Abstract][Full Text] [Related]
11. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
12. CNPY2 enhances resistance to apoptosis induced by cisplatin via activation of NF-κB pathway in human non-small cell lung cancer.
Yu D; Qin Y; Jun-Qiang L; Shun-Lin G
Biomed Pharmacother; 2018 Jul; 103():1658-1663. PubMed ID: 29864955
[TBL] [Abstract][Full Text] [Related]
13. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
14. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
15. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
16. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
19. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]